Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

Autoimmunity Reviews

Volumn 11, Issue 1, 2011, Pages 35-39

  Miserocchi, E ^a   Pontikaki, I ^b   Modorati, G ^a   Gattinara, M ^b   Meroni, P L ^b   Gerloni, V ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Juvenile idiopathic arthritis; Ocular inflammatory diseases; Rituximab

Indexed keywords

ADALIMUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EYE INFLAMMATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRAOCULAR LYMPHOMA; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; KERATITIS; KERATOCONJUNCTIVITIS; LOW DRUG DOSE; LYMPHOMA; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE SCLEROSIS; NECROTIZING SCLERITIS; NONHUMAN; OCULAR CICATRICIAL PEMPHIGOID; PERIPHERAL ULCERATIVE KERATITIS; REVIEW; RHEUMATOID ARTHRITIS; SCLERITIS; SEPTICEMIA; SERUM SICKNESS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UVEITIS; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ARTHRITIS, JUVENILE RHEUMATOID; CLINICAL TRIALS AS TOPIC; EYE DISEASES; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 80855138673     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.07.001     Document Type: Review

References (42)

1. Blank M., Shoenfeld Y. B cell targeted therapy in autoimmunity. J. Autoimmun. 2007, 28:62-68.
2. Perosa F., Favoino E., Caragnano M.A., Prete M., Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun. Rev. 2005, 4:526-531.
3. Bosello S., De Luca G., Tolusso B., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun. Rev. Apr 22 2011, [Epub ahead of print].
4. De Vita S., Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev. 2006, 5:443-448.
5. Dörner T., Isenberg D., Jayne D., Wiendl H., Zillikens D., Burmester G. International roundtable on B cells as therapeutic target for intervention. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun. Rev. 2009 Dec, 9(2):82-89.
6. Benucci M., Manfredi M., Puttini P.S., Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?. Autoimmun. Rev. 2010 Oct, 9(12):801-803.
7. Emery P., Fleishmann R., Filipowicz A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006, 54:1390-1400.
8. Smolen J.S., Keystone E.C., Emery P., Breedveld F.C., Betteridge N., Burmester G.R. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:143-150.
9. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 2005, 31:456-473.
10. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F., Zaramella M., Monti M., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun. Rev. May 5 2011, [Epub ahead of print].
11. Kong J.S.W., Teuber S.S., Gershwin M.E. Potential adverse events with biologic response modifiers. Autoimmun. Rev. 2006, 5:471-485.
12. Garcia-Carrasco M., Jimenez-Hernandez M., Escarcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M. Use of rituximab in systemic lupus erythematosus: an update. Autoimmun. Rev. 2009, 8:343-348.
13. Conti F., Perricone C., Ceccarelli F., Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun. Rev. 2010, 9:716-720.
14. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006, 45:1432-1436.
15. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005, 257:540-548.
16. Tobon G.J., Per J.O., Youinou P., Saraux A. B cell-targeted therapies in Sjogren's syndrome. Autoimmun. Rev. 2010, 9:224-228.
17. Quartuccio L., Fabris M., Salvin S., Maset M., De Marchi G., De Vita S. Controversies on Rituximab therapy in Sjogren syndrome-associated lymphoproliferation. Int. J. Rheumatol. 2009, 10:1-8.
18. Onal S., Kazokoglu H., Koc A., Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul. Immunol. Inflamm. 2008, 16:230-232.
19. Ai M., Gross W.L., Ahmadi-Simab K., Lamprecht P., Nolle B. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann. Rheum. Dis. 2005, 64:1087-1088.
20. Cheung C.M., Murray P.I., Savage C.O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br. J. Ophthalmol. 2005, 89:1542.
21. Taylor S.R.J., Salama A.D., Joshi L., Pusey C.D., Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009, 60:1540-1547.
22. Aries P.M., Hellmich B., Voswinkel J., Both M., Nölle B., Holl-Ulrich K. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 2006, 65:853-858.
23. Kurz P.A., Suhler E.B., Choi D., Rosenbaum J.T. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br. J. Ophthalmol. 2009, 93:546-548.
24. Freidlin J., Wong I.G., Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br. J. Ophthalmol. 2007, 91:1414.
25. Huerva V., Sanchez M.C., Traveset A., Jurjo C., Ruiz A. Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea 2010, 29(6):708-710.
26. Tappeiner C., Heinz C., Specker C., Heilighenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res. 2007, 39:184-186.
27. Davatchi F., Shams H., Rezaipoor M., Sadeghi-Abdollahi B., Shahram F., Nadji A., et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int. J. Rheum. Dis. 2010, 13:246-252.
28. Sadreddini S., Noshad H., Molaeefard M., Noshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod. Rheumatol. 2008, 18:306-308.
29. Hickman R.A., Denniston A.K., Yee C.S., Toescu V., Murray P.I., Gordon C. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus 2010, 19:327-329.
30. Anhalt G.J., Morrison L.H. Bullous and cicatricial pemphigoid. J. Autoimmun. 1991, 4:17-35.
31. Foster C.S., Chang P.Y., Ahmed R.M. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. A preliminary report. Ophthalmology 2010, 117:861-869.
32. Kitzmann A.S., Pulido J.S., Mohney B.G., Baratz K.H., Grube T., Marler R.J. Intraocular use of rituximab. Eye 2007, 21:1524-1527.
33. Ohguro N., Hashida N., Tano Y. Effect of intravitreous rituximab injections in patients with ocular lesions associated with central nervous system lymphoma. Arch. Ophthalmol. 2008, 126:1002-1003.
34. Kump L.I., Cervantes Castaneda R.A., Androudi S.N., Foster C.S. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006, 113:1874-1877.
35. Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B., et al. Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 2007, 34:1146-1150.
36. Gerloni V., Pontikaki I., Gattinara M., Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann. Rheum. Dis. 2008, 67:1145-1152.
37. Gallagher M., Quinones K., Cervantes-Castañeda R.A., Yilmaz T., Foster C.S. Biological response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 2007, 91:1341-1344.
38. Barnes M.G., Grom A.A., Thompson S.D., Griffin T.A., Pavlidis P., Itert L., et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60:2102-2112.
39. Miserocchi E., Pontikaki I., Modorati G., Bandello F., Meroni P.L., Gerloni V. Rituximab for uveitis. Ophthalmology 2011, 118:223-224.
40. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004, 31:390-392.
41. The standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first International workshop. Am. J. Ophthalmol. 2005, 140:509-516.
42. Miserocchi E., Baltatzis S., Ekong A., Roque M., Foster C.S. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002, 109:137-142.